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Abstract 
Malignant mesothelioma (MM) causes significant morbidity and mortality in patients. With 
increasing efforts devoted to developing therapeutics targeting mesothelioma, a xenograft 
mouse  model  with  in vivo tumor  imaging  is  especially  desired  for  evaluating anti-tumor 
therapies. In the present study, we fluorescently labeled the NCI-H226 human mesothelioma 
cell line by a lentiviral vector harboring a luciferase-GFP (Luc/GFP) fusion gene driven by the 
RNA polymerase II promoter. After single-cell cloning by flow cytometry, a clone (named 
LMB-H226-GL) that stably expresses high levels of Luc/GFP was obtained. The in vivo tu-
morigenicity of Luc/GFP-labeled LMB-H226-GL was determined by using intraperitoneal in-
jections of the cells in nude mice. LMB-H226-GL was found to be able to consistently form 
solid tumors in the peritoneum of mice. Tumor growth and aggressive progression could be 
quantitated via in vivo bioluminescence imaging. The model exhibited the pathological hall-
marks consistent with the clinical progression of MM in terms of tumor growth and spread 
inside the peritoneal cavity. To evaluate the in vivo efficacy of drugs targeting mesothelioma, 
we treated mice with SS1P, a recombinant immunotoxin currently evaluated in Phase II clinical 
trials for treatment of mesothelioma. All the tumor-bearing mice had a significant response to 
SS1P treatment. Our results showed that this is a well-suited model for mesothelioma, and 
may be useful for evaluating other novel agents for mesothelioma treatment in vivo. 
Key words: H226/NCI-H226, mouse xenograft model, in vivo bioluminescence imaging, malignant 
mesothelioma, mesothelin, monoclonal antibody, immunotoxin, preclinical model 
Introduction 
Malignant mesothelioma (MM) is a fatal asbes-
tos-associated  malignancy.  It  commonly  originates 
from the mesothelial cells lining the pleural and peri-
toneal cavities, as well as the pericardium and tunica 
vaginalis  testis  [1].  Although  combination  chemo-
therapy  with  pemetrexed  plus  cisplatin  has  been 
shown to be effective, the median overall survival of 
these patients is only 12 months [1]. One of the prom-
ising approaches that may improve patient outcome 
involves the use of monoclonal antibodies (mAb) [2]. 
Mesothelin  is  a  glycosyl-phosphatidylinositol 
(GPI)–anchored cell surface glycoprotein. It was first 
identified  in  1992  by  a  mAb  generated  by  the  im-
munization  of mice  with  human ovarian carcinoma 
cells [3]. The mesothelin gene encodes a 71-kDa pre-
cursor  protein  that  is  processed  to  a  40-kDa  mem-
brane-bound  protein  and  a  31-kDa  fragment  (a 
megakaryocyte-potentiating  factor)  that  is  released 
from the cell after furin cleavage [4, 5]. Mesothelin is a 
differentiation antigen whose expression is limited to Journal of Cancer 2011, 2 
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mesothelial  cells  lining  the  body  cavity  [6,  7].  It  is 
overexpressed in a variety of cancers including mes-
othelioma, ovarian cancer, and pancreatic cancer. In 
addition,  mesothelin  is  expressed  on  the  surface  of 
lung  adenocarcinomas  [8,  9].  Recently,  our  prelimi-
nary studies have shown that mesothelin is a potential 
therapeutic target in cholangiocarcinoma (CCA) [10]. 
We  have  demonstrated  strong  immunochemical 
mesothelin  staining  in  about  30%  of  the  surgically 
resected CCA specimens.  No mesothelin staining is 
present  in  hepatocelluar  carcinoma  or  normal  liver 
tissue. Mesothelin is primarily localized to the cellular 
plasma membrane and the mature form (~40 kDa) is 
expressed  at  a  high  level  in  CCA  tissues.  We  and 
others have shown that mesothelin is shed from tu-
mor cells [11, 12]. Given its link to tumor cells, serum 
mesothelin has been approved by the U.S. Food and 
Drug  Administration  for  use  as  a  diagnostic  bi-
omarker in MM. 
The limited distribution of mesothelin on normal 
tissues makes it a promising target for antibody-based 
immunotherapy.  Pastan  and  colleagues  have  devel-
oped a recombinant immunotoxin (named SS1P) that 
targets  mesothelin-expressing  tumors.  It  contains  a 
murine SS1 Fv fused to a 38-kDa fragment of Pseudo-
monas  exotoxin  A  (PE38)  [13].  Two  Phase  I  clinical 
trials of single agent SS1P have been completed at the 
National Cancer Institute (NCI) , National Institutes 
of  Health  (NIH)  in  Bethesda,  MD  and  is  currently 
being  evaluated  in  combination  with  chemotherapy 
for treatment of patients with mesothelioma [14, 15]. 
A  chimeric  antibody  (MORAb-009)  containing  the 
same murine SS1 Fv specific for mesothelin was also 
developed and is currently being examined in a Phase 
II clinical trial for mesothelioma and pancreatic cancer 
[7,  16].  We  have  recently  generated  a  high  affinity 
fully human IgG (named HN1) specific for mesothelin 
[17].  HN1  kills  cancer  cells  with  very  strong  anti-
body-dependent cell-mediated cytotoxicity. The HN1 
epitope is different from that of SS1. HN1 binds to cell 
surface-associated  mesothelin  on  human  mesotheli-
oma, ovarian cancer, lung adenocarcinoma and pan-
creatic cancer cells. 
Despite  such  advances  in  mesothelin-targeted 
cancer therapy, the biological functions of mesothelin 
remain largely unknown given that there are no ap-
parent  abnormalities  in  mesothelin  knockout  mice 
[18].  Nevertheless,  mesothelin  interacts  with  mucin 
MUC16  (also  known  as  CA125)  [19,  20],  indicating 
that  mesothelin  may  play  an  important  role  in  the 
metastatic spread of mesothelin-bearing cancer cells 
in  the  peritoneal  cavity.  We  have  shown  that  it  is 
primarily the N terminus of the extracellular domain 
of mesothelin (residues 296–359) that is sufficient and 
necessary for binding to MUC16 [20]. We have found 
that  the  MUC16-binding  domain  can  effectively  in-
hibit heterotypic cancer cell adhesion, indicating that 
the domain is a good candidate for use as a potential 
antagonist  to  prevent  or  treat  peritoneal  malignant 
tumors. 
 Xenograft  models  are  important  tools  for  pre-
clinical  evaluation  of  SS1P  and  other  an-
ti-mesothelioma targeted therapies. Recently, Yanag-
ihara  et  al.  established  an  orthotopic  implantation 
mouse  model  of  pleural  mesothelioma  [21].  In  the 
present study, we engineered the human mesotheli-
oma  cell  line  NCI-H226  (named  LMB-H226-GL)  to 
express  very  high  levels  of  GFP-luciferase  fusion 
proteins  (Luc/GFP).  Using  the  resultant 
LMB-H226-GL cell line, we established an MM model 
in  nude  mice.  In  this  model,  tumor  growth  can  be 
precisely measured by non-invasive and very sensi-
tive in vivo bioluminescence imaging. Importantly, the 
pathological hallmarks of the model were consistent 
with the clinical progression of MM in terms of tumor 
growth and spread inside the peritoneal cavity. We 
further  examined  the  effectiveness  of  the  an-
ti-mesothelin  immunotoxin  SS1P  in  our  model.  We 
found that all of the mice with tumor burdens had 
significant  response  upon  SS1P  treatment,  as  evi-
denced by in vivo imaging and necropsy observance, 
which strongly supports the role that SS1P may have 
as a potent anti-mesothelioma drug candidate. 
Materials and Methods  
Cell lines  
The  human  mesothelioma  cell  line  NCI-H226 
was obtained from the American Type Culture Col-
lection  (ATCC,  Rockville,  MD).  The  cell  line  was 
maintained as adherent monolayer cultures in RPMI 
1640  medium  (Invitrogen,  Carlsbad,  CA)  supple-
mented with 10% fetal bovine serum (FBS) (HyClone, 
Logan,  UT),  1%  L-glutamine,  and  1%  penicil-
lin-streptomycin  (Invitrogen)  and  incubated  in  5% 
CO2  with  a  balance  of  air  at  37°C.  Cells  were  har-
vested  and  the  media  were  changed  twice  a  week. 
Cells were confirmed to be negative for mycoplasma.  
Generation of the LMB-H226-GL cell line  
The NIH Institutional Biosafety Committee ap-
proved  the  Recombinant  DNA  Registration  Docu-
ment (RD-08-IX-07) for the following experiment and 
animal studies using the LMB-H226-GL cell line. The 
lentiviral  vectors  containing  a  plasmid  (plen-
ti4-B1-pPol2-B3-fluc-eGFP-B2) encoding the Luc/GFP 
were prepared by Viral Technology Laboratory, Ad-
vanced Technology Program, SAIC-Frederick, Inc. as 
previously described [22].  Journal of Cancer 2011, 2 
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Lentiviral supernatant was added into a culture 
plate containing 20–40% confluent parental NCI-H226 
cells. The plate was incubated at 37°C and the me-
dium changed the following day. Two days after in-
fection,  GFP  expression  was  examined  by  flow  cy-
tometry. At day 10, only cells showing the top 5% of 
high GFP expression were collected by flow cytome-
try. After single-cell cloning, the highest GFP expres-
sion  clone  (LMB-H226-GL)  was  selected  and  main-
tained in RPMI 1640 media supplemented with 10% 
FBS, 1% glutamine, and 1% streptomycin/penicillin.  
Cell growth inhibition assays  
Cell growth inhibition was assessed by WST-8 
assay  using  the  Cell  Counting  Kit-8  (Dojindo, 
Gaithersburg,  MD)  according  to  the  manufacturer's 
instructions.  Two  hundred  microliters  of  either 
NCI-H226  or  LMB-H226-GL  cells  were  seeded  at 
1x104 cells per well into a 96-well plate, with the ad-
dition of SS1P at the indicated concentrations. Cells 
were incubated at 37°C for 72 hours, followed by a 
cytotoxicity assay.  
Flow cytometry  
Cells were harvested in cell dissociation solution 
(Invitrogen),  washed,  and  resuspended  in  ice-cold 
phosphate buffered saline (PBS) containing 5% bovine 
serum  albumin  (BSA).  Cells  were  incubated  with  5 
μg/mL of MN (mesothelin mAb; cat. # 200-301-A88; 
Rockland,  Gilbertsville,  PA).  Binding  was  detected 
with  goat  anti-mouse  IgG  conjugated  with  phyco-
erythrin (Sigma-Aldrich, St. Louis, MO). The fluores-
cence associated with the live cells was measured us-
ing a FACSCalibur flow cytometer (BD Biosciences, 
San Jose, CA). 
Animal experiments  
The  NCI-Bethesda  Animal  Study  Proposal 
(LMB-059)  was  approved  by  the  NIH  Animal  Care 
and  Use  Committee.  Six-week  old  female  athymic 
nude  mice  (ATHYMIC  NCr-nu/nu)  obtained  from 
the National Cancer Institute-Frederick Animal Pro-
duction  Area  (Frederick,  MD)  were  housed  in  mi-
cro-isolator  cages  throughout  the  course  of  the  ex-
periment. The mice were maintained per the institu-
tional guidelines of the NIH. Five (low-dosage group) 
or 10 (high-dosage group) million LMB-H226-GL cells 
in 500 μl of growth media were injected intraperito-
neally (i.p.) per mouse.  
In vivo bioluminescence measurements 
Tumor sizes were assessed via in vivo biolumi-
nescence measurement using the IVIS  Imaging Sys-
tem  (Caliper  Life  Sciences,  Hanover,  MD).  For  the 
luciferase  detection  imaging,  200  μl  of  15  mg/mL 
D-luciferin (Caliper Life Sciences) in PBS was injected 
i.p. before imaging. The photometry of the tumor was 
calculated  by  software  Living  Image  3.1.0,  (Caliper 
Life Sciences) and the results were used to generate 
the  tumor  growth  curve.  To  correlate  fluorescence 
intensity and tumor size, tumor dimensions were de-
termined using calipers, and the tumor volume (mm3) 
was calculated by the formula: length x (width) 2 x 0.4. 
Necropsy and histopathology 
At the end of the in vivo tumor growth study, a 
subset  of  mice  from  control  and  treatment  groups 
were euthanized with CO2, the abdominal cavity was 
opened, and a photo of the tumor in situ was taken. A 
complete necropsy was performed with collection of 
all major organs and tissues as well as gross lesions 
suggestive  of  neoplasia.  Tissues  were  fixed  in  10% 
buffered neutral formalin, processed to paraffin and 
sectioned at 5 microns. Slides were stained with he-
matoxylin  and  eosin  (H&E)  or  used  for  immuno-
histochemistry. 
 Two  antibodies  were  used:  anti-mesothelin  to 
confirm the identity of the cell line and anti-GFP to 
correlate  with  in  vivo  images.  Mesothelin  (Sig-
ma-Aldrich,  cat.  #HPA017172)  made  in  rabbit  was 
diluted 1:300 and incubated on sections for 30 minutes 
at room temperature. Staining was achieved on the 
Leica Biosystems Bond Autostainer using normal goat 
serum  and  biotin-conjugated  secondary  antibody 
goat/anti-rabbit  from  Vector  Laboratories  (Burlin-
game,  CA).  Pretreatment  consisted  of  citrate 
heat-induced epitope retrieval. The Intense R Detec-
tion Kit was used with the Autostainer. 
 The anti-GFP antibody made in rabbit was ob-
tained from Abcam (cat. #ab6556, Cambridge, MA). 
Manual staining was performed and the antibody was 
diluted  1:5000  and  incubated  on  sections  for  30 
minutes at 37oC. Pretreatment included normal goat 
serum,  and  biotin-conjugated  goat  anti-rabbit  sec-
ondary antibody from Vector Laboratories was used, 
with diamino benzidine as chromagen and hematox-
ylin as a counter-stain. 
 Pathology  evaluation  was  performed  by  a 
board-certified veterinary pathologist and correlated 
with in vivo images. 
Immunotoxin treatment 
Two  treatment  groups  and  one  control  group 
were  set  up  with  eight  mice  in  each  group.  Each 
mouse  was  initially  i.p.  injected  with  10  million 
LMB-H226-GL cells in 500 μl of growth media. Each 
mouse in the  treatment groups received 0.4 mg/kg 
SS1P  in  PBS  buffer  and  the  control  group  received 
PBS.  One  treatment  group  (treatd1)  was  started  on Journal of Cancer 2011, 2 
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day one (the day when the mice received the cells was 
set as day 1) then received four further doses of SS1P 
every  other  day  thereafter.  The  second  treatment 
group  (treatd9)  was  started  on  day  nine,  and  then 
received three further doses of SS1P as in the treatd1 
group. Suppression of tumor growth was measured 
by in vivo imaging. 
Statistical analysis 
Statistical  analysis  was  performed  with  Prism 
(version 5) for Windows (GraphPad Software). Raw 
data  were  analyzed  by  “analysis  of  variance”  with 
Dunnett's  and  Newman-Keuls  multiple  comparison 
post tests. p values < 0.05 were considered statistically 
significant. 
Results  
Generation and characterization of the 
LMB-H226-GL cell line  
NCI-H226, as one of the NCI-60 cell lines, is a 
well characterized mesothelioma cell line with high 
expression levels of mesothelin. Deemed suitable for 
establishing  our  model,  the  NCI-H226  cells  were 
transfected  with  a  lentiviral  vector  that  harbors  the 
Luc/GFP  fusion  gene  under  the  control  of  RNA 
polymerase II promoter (Pol2). After three rounds of 
sorting by flow cytometry and single-cell cloning, a 
clone (named LMB-H226-GL) with a very high level 
of  GFP  expression  was  obtained  (Fig.  1A).  The  re-
sultant LMB-H226-GL cell line was then evaluated for 
cell surface expression of mesothelin and sensitivity to 
the SS1P immunotoxin. No differences were observed 
in  mesothelin  expression  levels  between  NCI-H226 
and LMB-H226-GL (Fig. 1B). In addition, there were 
no significant differences between the IC50 values of 
NCI-H226  and  LMB-H226-GL.  The  IC50  value  for 
LMB-H226-GL  was  0.6  ng/mL  and  0.4  ng/mL  for 
NCI-H226  (Fig.  1C).  Thus,  we  determined  that  the 
LMB-H226-GL line may be appropriately used for in 
vivo studies of mesothelin-targeted drugs.  
In vivo imaging of tumor growth  
To  check  the  tumorigenicity  of  LMB-H226-GL, 
we designed two groups of mice based on the num-
bers of cells injected: the high-dosage group (10 mil-
lion  cells  per  mouse)  (Fig.  2a)  and  the  low-dosage 
group  (5  million  cells  per  mouse)  (Fig.  2b).  The 
growth rate of the high-dosage group was similar to 
that of the low-dosage group. The tumor size in the 
high-dosage group was relatively larger (Fig. 3a) at 
the same time point. 
 
 
 
 
Fig. 1. In vitro characterization of LMB-H226-GL cells. A. FACS analysis showing GFP fluorescence in the LMB-H226-GL cell 
line. Shaded area: parental NCI-H226; heavy solid line: LMB-H226-GL. B. Mesothelin expression on LMB-H226-GL. Shaded 
area:  NCI-H226  without  anti-mesothelin  staining;  thin  dotted  line:  LMB-H226-GL  without  staining;  heavy  solid  line: 
NCI-H226 with staining; heavy dotted line: LMB-H226-GL with staining. C. WST-8 assay of NCI-H226 and LMB-H226-GL. 
Various amounts of SS1P immunotoxin were used to treat NCI-H226 and LMB-H226-GL cells.  
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Fig. 2. In vivo imaging of LMB-H226-GL tumors in nude mice. A. High-dosage group, each mouse received 10 million cells. 
Animals were imaged the following day (d2) and then once every week thereafter. B. Low-dosage group, each mouse 
received five million cells and were imaged following the same schedule as the high-dosage group.  Journal of Cancer 2011, 2 
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Fig. 3. In vivo tumor growth curve. A. Tumor growth was measured by bioluminescence photometry. The day when the 
mice were injected with the tumor cells was set as d1. The photometry of the in vivo imaging was accumulated by software 
Living Image 3.1.0 (Caliper Life Sciences) and the resulting photon counts were plotted as the Y-axis. Error bars represent 
the standard deviation from measurement of four mice in each corresponding group. At the end of the study, mice were 
sacrificed; tumors were immediately removed and measured by weight, size and fluorescence. Association of photon in-
tensity with tumor weight (B) or size (C) was also performed. A stronger correlation between bioluminescence and tumor 
weight is shown (correlation coefficients are 0.77 for weight and 0.57 for size). 
 
 
 
The distribution of luminescence was irregular 
in  the  abdomen  at  the  beginning  and  the  tumors 
eventually spread to fill the entire abdomen (Fig. 2). 
At day 60 (high-dosage group) or day 67 (low-dosage 
group), most of the mice were thin, sick, and less ac-
tive,  indicating  the  end-point  of  the  experiment. 
During the whole study, only one mouse was found 
to  have  a  distended  abdomen,  but  no  ascites  was 
found in the abdomen. 
A dual reporter system may greatly enhance the 
value of mouse cancer models as shown by Dai et al. 
[22]. In the present study, we used the same previ-
ously well-established vector [22]. The LMB-H226-GL 
cells highly coexpressed Luc/GFP. We used luciferase 
to quantitate in vivo tumor growth. The light emission 
of the luciferase system can be detected in the imager 
after i.p. injection of  the substrate  luciferin into the 
mouse.  The  signal  quickly  reached  its  peak  three 
minutes after injection, and the peak was maintained 
for at least 30 minutes. As for the GFP reporter, it may 
be  particularly  useful  to  isolate  mesothelioma  cells 
from mice by flow cytometry after forming tumors as 
previously shown [22] and to investigate the molecu-
lar  oncogenesis  of  mesothelioma  by  analyzing  the 
changes in gene expression profiles.  
At the end of the experiment, the mice were eu-
thanized, and tumors were immediately removed and 
measured by weight (Fig. 3B) and volume (Fig. 3C). 
We compared the photon intensity with tumor weight 
and volume, and found that comparing the biolumi-
nescence  (photons/sec)  to  tumor  weight  formed  a 
better  correlation  than  comparing  the  biolumines-
cence to tumor size (correlation coefficients were 0.77 
and 0.57, respectively). 
Necropsy and histopathology 
At necropsy, white mesothelioma tumors were 
attached  to  and  sometimes  invaded  the  peritoneal 
wall  (Fig.  4A).  Similar  masses  were  present  on  the 
visceral peritoneum of the pancreas, liver, diaphragm 
and gonadal fat pads. 
Histopathological  evaluation  confirmed  the 
mesothelioma attributes of the injected cell line. On 
H&E,  mesotheliomas  in  the  peritoneal  cavity  were 
composed  of  sheets  of  cells  with  eosinophilic  cyto-
plasm and large atypical nuclei with prominent nu-
cleoli  (Fig.  4B).    Immunohistochemistry  using  the 
anti-mesothelin  antibody  showed  strong  membrane 
and  some  cytoplasmic  staining  (Fig.  4C).  With  the 
anti-GFP antibody, there was mild to moderate cyto-
plasmic staining (Fig. 4D).  
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Fig. 4. Necropsy and histological observance. A. Mesothelioma in peritoneal cavity. Arrow indicates the tumor mass. B. 
H&E staining (20x). C. Mesothelin IHC (20x) with membrane staining. D. GFP IHC (20x) with cytoplasmic staining. 
 
Immunotoxin treatment  
As a proof-of-concept experiment, we tested in 
vivo anti-tumor activity using SS1P in the established 
mesothelioma  model.  The  treatment  was  designed 
based on clinical regimens. One treatment started on 
day one (the day when the mice received cells was set 
as  day1),  which  may  represent  those  patients  who 
receive SS1P immediately after surgery to remove the 
visible tumor tissues, but may have remnant tumor 
cells that may cause relapse. Another treatment began 
on  day  9,  which  may  represent  the  early  stages  of 
MPM. A dramatic decrease of bioluminescence can be 
seen in both treatments two days after the first SS1P 
injection (Fig. 5).  
 
 
Fig. 5. SS1P treatment. Each mouse was i.p. injected with 
10 million cells. At day 1 (treatd1) or day 9 (treatd9), the 
mice were given the first SS1P treatment by i.p. injection at 
a dose of 0.4 mg/kg body weight. The treatments were 
performed  every  other  day  as  indicated  by  arrows. 
*Indicates  the  significant  (p  <  0.05)  difference  between 
treatment and control by using the one-way ANOVA sta-
tistical test (GraphPad Prism 5.03). 
 
There was a significant difference between  the 
treatment and control groups. Lungs were examined 
microscopically from the subset of mice. Interestingly, 
50% of the control group (2/4) and none of the treated 
groups  (0/6)  had  mesothelioma  micrometastases. 
Neither of the treatment groups completely eradicat-
ed the tumor cells. We speculated that this might be 
due to an acquired apoptotic drug resistance to SS1P 
after treatment; however, we did not find changes in 
sensitivity  to  SS1P  using  the  surviving  tumor  cells 
grown as monolayers for in vitro cytotoxicity assays 
on culture dishes (data not shown).  
Discussion  
We  generated  a  Luc/GFP-expressing  mesothe-
lioma  cell  line,  LMB-H226-GL.  The  LMB-H226-GL 
line is able to form solid tumors seeded in the perito-
neal  cavity  of  nude  mice,  which  exhibited  similar 
characteristics of human MM. The growth and spread 
of tumors can be noninvasively monitored by in vivo 
bioluminescent imaging.  
SS1P was previously tested in ecotopic (subcu-
taneous) mouse models [23, 24]. These models used a 
transfected  non-mesothelioma  cell  line  (A431)  that 
highly expresses mesothelin (~1×106 sites per cell), as 
inoculums. Regardless, these may not be ideal models 
given that both the genetic background and antigen 
(mesothelin) expression levels are different from those 
of  native  mesothelioma  cells.  In  addition,  ectopic 
models  use  manual  callipering  for  tumor  measure-
ment,  which  may  introduce  manual  deviation  de-
pending  on  the  operator.  On  the  other  hand, 
LMB-H226-GL tumor cells express Luc/GFP at a very 
high level allowing for in vivo human mesothelioma 
tumors to be measured directly. This can be accom-
plished according to either luciferase or GFP fluores-
cence using an in vivo bioluminescence imaging sys-
tem. As such, we believe that this new model intro-
duces an improved method for the evaluation of an-
ti-mesothelioma therapeutics. Journal of Cancer 2011, 2 
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Advances in antibody-based therapies represent 
a promising new approach to treating solid cancers, 
but a major challenge involves delivering a sufficient 
amount  of  antibody  and  immunoconjugate  to  the 
tumor mass [25]. For an anti-cancer antibody agent to 
be  successful,  it  must  satisfy  two  requirements:  the 
agent must be effective in the tumor microenviron-
ment,  and  the  agent  must  reach  the  tumor  cells  in 
optimal  quantities.  In  the  present  study,  the  SS1P 
treatment  alone  exhibited  significant  an-
ti-mesothelioma activity. However, it was not able to 
completely  eradicate  tumors.  We  found  that  SS1P 
bound to the remaining tumor cells and killed them 
with  similar  activity  when  tested  in  vitro  as  tumor 
monolayers (data not shown). In a recent study, we 
examined how the tumor microenvironment affected 
the  penetration  and  killing  activity  of  SS1P  in  a 
three-dimensional  (3D)  spheroid  model  cultured  in 
vitro using NCI-H226 and two primary cell lines iso-
lated from the ascites of MM patients [26]. Mesothe-
lioma cells grown as monolayers or as spheroids ex-
pressed  comparable  levels  of  mesothelin;  however, 
spheroids  were  at  least  100  times  less  affected  by 
SS1P. We examined the time course of SS1P penetra-
tion  within  spheroids.  The  penetration  was  limited 
after  4  hours.  Interestingly,  we  found  a  significant 
increase in the number of tight junctions in spheroids. 
Expression of E-Cadherin, a protein involved in the 
assembly  and  sealing  of  tight  junctions  and  highly 
expressed in MM, was found significantly increased 
in spheroids as compared to monolayers. Moreover, 
we found that siRNA silencing and antibody inhibi-
tion targeting E-Cadherin could enhance SS1P thera-
py in vitro. Further studies will be needed to under-
stand  the  molecular  mechanisms  underlying  drug 
resistance  and  for  innovative  combinations  of  SS1P 
with agents that can increase the penetration of drugs 
and allow for sufficient amounts of SS1P to reach the 
tumor cells. 
Acknowledgements 
This work was supported in part by the Intra-
mural Research Program of the National Institutes of 
Health, National Cancer Institute, Center for Cancer 
Research,  in  part  by  a  Mesothelioma  Applied  Re-
search Foundation Grant in Honor of Craig Kozicki to 
MH, and in part by the National Cancer Institute, NIH 
under contract No. HHSN261288800001E. 
We thank Ira Pastan (NCI, NIH) for helpful dis-
cussions, Betty Ortiz-Conde (Gene Expression Labor-
atory, SAIC-Frederick, Inc.) for producing lentivirus, 
Bih-Rong Wei (NCI, NIH) for technical assistance in in 
vivo tumor imaging, Barbara Taylor (NCI Flow Cy-
tometry  Core,  NIH)  for  technical  assistance  in  flow 
cytometry,  and  Donna  Butcher  (Patholo-
gy/Histotechnology Laboratory, SAIC-Frederick) for 
immunohistochemistry technical assistance. We also 
thank the NIH Fellows Editorial Board for their re-
view of the manuscript, Yen Phung (NCI, NIH) and 
Anna  Mazzuca  (NCI,  NIH)  for  editorial  assistance. 
The content of this publication does not necessarily 
reflect  the  views  or  policies  of  the  Department  of 
Health  and  Human  Services,  nor  does  mention  of 
trade names, commercial products, or organizations 
imply endorsement by the U.S. Government. 
Conflict of Interest 
The authors declare that they have no conflict of in-
terest. 
References 
1.  Robinson BWS, Lake RA. Advances in malignant mesothelio-
ma. N Engl J Med 2005;353:1591-603. 
2.  Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A. 
Second-line  treatment  for  malignant  pleural  mesothelioma. 
Cancer Treat Rev 2010;36:24-32. 
3.  Chang K, Pastan I, Willingham MC. Isolation and characteriza-
tion of a monoclonal antibody, K1, reactive with ovarian can-
cers and normal mesothelium. Int J Cancer 1992;50:373-81.  
4.  Chang K, Pastan I. Molecular cloning of mesothelin, a differen-
tiation  antigen  present  on  mesothelium,  mesotheliomas,  and 
ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40. 
5.  Hassan R, Bera T, Pastan I. Mesothelin: a new target for im-
munotherapy. Clin Cancer Res 2004;10:3937-42. 
6.  Ho M, Hassan R, Zhang J, Wang Q, Onda M, Bera T, Pastan I. 
Humoral immune response to mesothelin in mesothelioma and 
ovarian cancer patients. Clin Cancer Res 2005;11:3814-20. 
7.  Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. 
Eur J Cancer 2008;44:46-53. 
8.  Ordonez  NG.  Application  of  mesothelin  immunostaining  in 
tumor diagnosis. Am J Surg Pathol 2003;27:1418–28. 
9.  Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGer-
ald D, Pastan I. Mesothelin expression in human lung cancer. 
Clin Cancer Res 2007;13:1571-5. 
10.  Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, Qian M, 
Wang XW, Ho M. Mesothelin as a potential therapeutic target 
in human cholangiocarcinoma. J Cancer 2010;1:141-9. 
11.  Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, Klerk 
N,  Winzell  P,  Hellstrom  KE,  Hellstrom  I.  Mesothelin-family 
proteins  and  diagnosis  of  mesothelioma.  Lancet 
2003;362:1612-16. 
12.  Ho M, Onda M, Wang Q, Hassan R, Pastan I, Lively M. Meso-
thelin is shed from tumor cells. Cancer Epidemiol Biomarkers 
Prev 2006;15:1751. 
13.  Chowdhury PS, Pastan I. Improving antibody affinity by mim-
icking  somatic  hypermutation  in  vitro.  Nat  Biotechnol 
1999;17:568-72. 
14.  Hassan R, Bullock S, Premkumar A, Kreitman RJ., Kindler H, 
Willingham MC, Pastan I. Phase I study of SS1P, a recombinant 
anti-mesothelin immunotoxin given as a bolus I.V. infusion to 
patients  with  mesothelin-expressing  mesothelioma,  ovarian, 
and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.  
15.  Robert J. Kreitman, Raffit Hassan, David J. FitzGerald, Pastan I. 
Phase I trial of continuous infusion anti-mesothelin recombi-
nant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9. 
16.  Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao 
Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Do-Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
131 
nahue CI, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides 
NC, Grasso L. Preclinical evaluation of MORAb-009, a chimeric 
antibody  targeting  tumor-associated  mesothelin.  Cancer  Im-
mun 2007;7:20-30. 
17.  Ho  M,  Feng  M,  Fisher  RJ,  Rader  C,  Pastan  I.  A  novel 
high-affinity human monoclonal antibody to mesothelin. Int J 
Cancer 2010; [Epub ahead of print] 
18.  Bera TK, Pastan I. Mesothelin is not required for normal mouse 
development or reproduction. Mol Cell Biol 2000;20:2902-6.  
19.  Rump  A,  Morikawa  Y,  Tanaka  M,  Minami  S,  Umesaki  N, 
Takeuchi  M,  Miyajima  A.  Binding  of  ovarian  cancer antigen 
CA125/MUC16  to  mesothelin  mediates  cell  adhesion.  J  Biol 
Chem 2004;279:9190-8.  
20.  Kaneko O, Gong L, Zhang J, Hansen J, Hassan R, Lee B, Ho M. 
A  binding  domain  on  mesothelin  for  CA125/MUC16.  J  Biol 
Chem 2009;284:3739–49. 
21.  Yanagihara K, Tsumuraya M, Takigahira M, Mihara K, Kubo T, 
Ohuchi K, Seyama T. An orthotopic implantation mouse model 
of human malignant pleural mesothelioma for in vivo photon 
counting analysis and evaluation of the effect of S-1 therapy. Int 
J Cancer 2010;126:2835–46. 
22.  Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, 
Hollingshead M, Merlino G. Lentivirus-mediated bifunctional 
cell labeling for in vivo melanoma study. Pigment Cell Mela-
noma Res 2009;22:283-95.  
23.  Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, 
Le N, Ho M, Pastan I. Synergistic antitumor activity of taxol 
and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 
2006;12:4695-701. 
24.  Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. An-
ti-mesothelin immunotoxin SS1P in combination with gemcita-
bine results in increased activity against mesothelin-expressing 
tumor xenografts. Clin Cancer Res 2007;13:7166-71.  
25.  Jain  RK.  Transport  of  molecules,  particles, and  cells  in  solid 
tumors. Annu Rev Biomed Eng 1999;1:241-63.  
26.  Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus 
VC,  Hassan  R,  FitzGerald  D,  Ho  M.  The  development  and 
characterization of a human mesothelioma in vitro 3D model to 
investigate immunotoxin therapy. PLoS One 2011; 6:e14640.  